Adults with Blepharospasm

Overview Efficacy Safety Dosing

XEOMIN Safety Profile in the Treatment of Adults with Blepharospasm who were Previously Treated with OnabotulinumtoxinA (Botox)

Pivotal Study: Safety of XEOMIN vs placebo

Safety was demonstrated in a randomized, double-blind, placebo-controlled trial of XEOMIN® (incobotulinumtoxinA).1,2

Noninferiority Study: Safety was demonstrated in a randomized, double-blind, multicenter trial in patients previously treated with onabotulinumtoxinA (Botox).3

The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.

References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2018.
  2. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm–a randomized trial. Mov Disord. 2011;26(8):1521-1528.
  3. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303-312.